An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs ALKS 2680 (Primary)
- Indications Narcolepsy
- Focus Adverse reactions; Registrational
- Sponsors Alkermes plc
- 16 Jan 2025 New trial record